BR0315103A - Compostos de diidropiridina tendo capacidade simultânea de bloquear os canais de cálcio do tipo l e inibir a atividade da fosfodiesterase do tipo 3 - Google Patents
Compostos de diidropiridina tendo capacidade simultânea de bloquear os canais de cálcio do tipo l e inibir a atividade da fosfodiesterase do tipo 3Info
- Publication number
- BR0315103A BR0315103A BR0315103-4A BR0315103A BR0315103A BR 0315103 A BR0315103 A BR 0315103A BR 0315103 A BR0315103 A BR 0315103A BR 0315103 A BR0315103 A BR 0315103A
- Authority
- BR
- Brazil
- Prior art keywords
- type
- calcium channels
- compounds
- phosphodiesterase activity
- inhibit
- Prior art date
Links
- 108090000312 Calcium Channels Proteins 0.000 title abstract 2
- 102000003922 Calcium Channels Human genes 0.000 title abstract 2
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 title abstract 2
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 title abstract 2
- 230000000694 effects Effects 0.000 title abstract 2
- 125000004925 dihydropyridyl group Chemical class N1(CC=CC=C1)* 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 101100135867 Caenorhabditis elegans pde-3 gene Proteins 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 102000004016 L-Type Calcium Channels Human genes 0.000 abstract 1
- 108090000420 L-Type Calcium Channels Proteins 0.000 abstract 1
- 208000019695 Migraine disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 206010015037 epilepsy Diseases 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 206010027599 migraine Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
- C07D211/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/84—Nitriles
- C07D213/85—Nitriles in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/04—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having less than three double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41625402P | 2002-10-07 | 2002-10-07 | |
| PCT/US2003/031592 WO2004033444A1 (en) | 2002-10-07 | 2003-10-07 | Dihydropyridine compounds having simultaneous ability to block l-type calcium channels and to inhibit phosphodiesterase type 3 activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0315103A true BR0315103A (pt) | 2005-08-16 |
Family
ID=32093831
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0315103-4A BR0315103A (pt) | 2002-10-07 | 2003-10-07 | Compostos de diidropiridina tendo capacidade simultânea de bloquear os canais de cálcio do tipo l e inibir a atividade da fosfodiesterase do tipo 3 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US7098211B2 (enExample) |
| EP (1) | EP1554267A1 (enExample) |
| JP (1) | JP2006504738A (enExample) |
| KR (1) | KR20050070036A (enExample) |
| CN (1) | CN1720243A (enExample) |
| AU (1) | AU2003275450A1 (enExample) |
| BR (1) | BR0315103A (enExample) |
| CA (1) | CA2501534A1 (enExample) |
| MX (1) | MXPA05003640A (enExample) |
| NO (1) | NO20052169L (enExample) |
| PL (1) | PL376405A1 (enExample) |
| RU (1) | RU2005110062A (enExample) |
| WO (1) | WO2004033444A1 (enExample) |
| ZA (1) | ZA200502711B (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7094806B2 (en) * | 2000-07-07 | 2006-08-22 | Trustees Of Tufts College | 7, 8 and 9-substituted tetracycline compounds |
| WO2005016885A2 (en) * | 2003-08-14 | 2005-02-24 | Artesian Therapeutics, Inc. | COMPOUNDS WITH COMBINED CALCIUM CHANNEL BLOCKER AND β-ADRENERGIC ANTAGONIST OR PARTIAL AGONIST ACTIVITIES FOR TREATMENT OF HEART DISEASE |
| WO2005035505A2 (en) * | 2003-09-30 | 2005-04-21 | Artesian Therapeutics, Inc. | Compounds with phosphodiesterase inhibiting and calcium channel blocking activities |
| DE102004011512B4 (de) | 2004-03-08 | 2022-01-13 | Boehringer Ingelheim Vetmedica Gmbh | Pharmazeutische Zubereitung enthaltend Pimobendan |
| EP1579862A1 (en) | 2004-03-25 | 2005-09-28 | Boehringer Ingelheim Vetmedica Gmbh | Use of PDE III inhibitors for the reduction of heart size in mammals suffering from heart failure |
| US8980894B2 (en) | 2004-03-25 | 2015-03-17 | Boehringer Ingelheim Vetmedica Gmbh | Use of PDE III inhibitors for the treatment of asymptomatic (occult) heart failure |
| US20090298872A1 (en) * | 2004-12-13 | 2009-12-03 | Irm Llc | Compounds and compositions as modulators of steroidal receptors and calcium channel activities |
| NL1028564C2 (nl) * | 2005-03-17 | 2006-09-20 | Rademaker Holding B V | Toepassing van een coumarine-groep omvattende derivaten voor de bereiding van een antiviraal middel, coumarine-group omvattende derivaten, een werkwijze voor de bereiding daarvan, en farmaceutische preparaten die deze bevatten. |
| EP1920785A1 (en) | 2006-11-07 | 2008-05-14 | Boehringer Ingelheim Vetmedica Gmbh | Liquid preparation comprising a complex of pimobendan and cyclodextrin |
| CN101215258A (zh) * | 2008-01-21 | 2008-07-09 | 中国药科大学 | 二氢吡啶类钙拮抗剂化合物及其制备方法与医药用途 |
| WO2009149837A1 (en) | 2008-06-09 | 2009-12-17 | Bayer Schering Pharma Aktiengesellschaft | Substituted 4- (indazolyl) -1,4-dihydropyridines and methods of use thereof |
| WO2010060874A1 (en) * | 2008-11-25 | 2010-06-03 | Boehringer Ingelheim Vetmedica Gmbh | Phosphodiesterase type iii (pde iii) inhibitors or ca2+-sensitizing agents for the treatment of hypertrophic cardiomyopathy |
| WO2011071995A2 (en) | 2009-12-08 | 2011-06-16 | Case Western Reserve University | Compounds and methods of treating ocular disorders |
| GB201017783D0 (en) * | 2010-10-21 | 2010-12-01 | Shire Llc | Process for the preparation of anagrelide and analogues thereof |
| US10398705B2 (en) | 2012-03-15 | 2019-09-03 | Boehringer Ingelheim Vetmedica Gmbh | Pharmaceutical tablet formulation for the veterinary medical sector, method of production and use thereof |
| AU2014292086B2 (en) | 2013-07-19 | 2019-08-08 | Boehringer Ingelheim Vetmedica Gmbh | Preserved etherified cyclodextrin derivatives containing liquid aqueous pharmaceutical composition |
| MX375936B (es) | 2013-12-04 | 2025-03-07 | Boehringer Ingelheim Vetmedica Gmbh | Composiciones farmaceuticas mejoradas de pimobendan. |
| US10537570B2 (en) | 2016-04-06 | 2020-01-21 | Boehringer Ingelheim Vetmedica Gmbh | Use of pimobendan for the reduction of heart size and/or the delay of onset of clinical symptoms in patients with asymptomatic heart failure due to mitral valve disease |
| CR20200464A (es) | 2018-03-08 | 2021-04-14 | Incyte Corp | Compuestos diólicos de aminopirazina como inhibidores de pi3k-y |
| WO2020010003A1 (en) | 2018-07-02 | 2020-01-09 | Incyte Corporation | AMINOPYRAZINE DERIVATIVES AS PI3K-γ INHIBITORS |
| CN115838351B (zh) * | 2022-12-06 | 2025-01-28 | 昆明理工大学 | 4-烷基-1,4-二氢吡啶化合物及其制备方法和应用 |
| CN116693454B (zh) * | 2023-06-06 | 2026-06-05 | 中山大学 | 一种取代氰基喹啉酮类化合物及其制备方法与应用 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS57200386A (en) | 1981-06-04 | 1982-12-08 | Yoshitomi Pharmaceut Ind Ltd | Novel 1,4-dihydropyridine-3,5-dicarboxylic ester derivative and its salts |
| CH655110A5 (de) * | 1982-09-03 | 1986-03-27 | Otsuka Pharma Co Ltd | Carbostyrilderivate, verfahren zu deren herstellung und arzneimittel, welche diese enthalten. |
| PL140069B1 (en) | 1982-12-21 | 1987-03-31 | Pfizer | Method of obtaining new derivatives of dihydropiridine |
| GB8306666D0 (en) | 1983-03-10 | 1983-04-13 | Pfizer Ltd | Therapeutic agents |
| US4568677A (en) | 1983-07-23 | 1986-02-04 | Pfizer Inc. | 2-(4-Pyrimidone alkoxyalkyl) dihydropyridine anti-ischaemic and antihypertensive agents |
| DE3445852A1 (de) | 1984-12-15 | 1986-06-19 | Bayer Ag, 5090 Leverkusen | Dihydropyridin-carbonsaeureamide, verfahren zu ihrer herstellung und ihre verwendung in arzneimitteln |
| GB8501395D0 (en) | 1985-01-19 | 1985-02-20 | Pfizer Ltd | Dihydropyridine anti-ischaemic & anti-hypertensive agents |
| US4820842A (en) | 1986-11-19 | 1989-04-11 | Warner-Lambert Company | 2-substituted-1,4-dihydropyridines |
| US4723014A (en) | 1986-11-19 | 1988-02-02 | Warner-Lambert Company | Process for the preparation of 2-substituted-1,4-dihydropyridines |
| DE3712369A1 (de) | 1987-04-11 | 1988-10-27 | Bayer Ag | Substituierte 5-nitro-1,4-dihydropyridine, verfahren zur herstellung und ihre verwendung |
| DE3712371A1 (de) | 1987-04-11 | 1988-10-27 | Bayer Ag | Substituierte 1,4-dihydropyridine, verfahren zu ihrer herstellung und ihre verwendung |
| DE3716652A1 (de) | 1987-05-19 | 1988-12-08 | Bayer Ag | Dioxyalkylenaryl-dihydropyridine, zwischenprodukte zu ihrer herstellung, verfahren zu ihrer herstellung und ihre verwendung |
| DE3724909A1 (de) | 1987-07-28 | 1989-02-09 | Bayer Ag | Neue substituierte nitro-dihydropyridine, verfahren zu ihrer herstellung und ihre verwendung |
| US5096904A (en) | 1989-09-01 | 1992-03-17 | Glaxo Inc. | Pyridazinones having cardiotonic and beta blocking activities |
| WO1992006087A1 (en) | 1990-10-02 | 1992-04-16 | Kaken Pharmaceutical Co., Ltd. | Pyridazinone-substituted ethynylphenyl derivative and remedy for circulatory organ disease containing the same as active ingredient |
| US5100892A (en) | 1990-11-13 | 1992-03-31 | Glaxo Inc. | Dihydropyridine vasodilator agents |
| US5258519A (en) | 1990-11-13 | 1993-11-02 | Glaxo Inc. | Dihydropyridine vasodilators agents |
| MXPA03000436A (es) | 2000-07-18 | 2003-06-24 | Yamanouchi Pharma Co Ltd | Medicamentos que compreden derivados de dicianopiridina. |
| DE10110747A1 (de) | 2001-03-07 | 2002-09-12 | Bayer Ag | Substituierte 2,6-Diamino-3,5-dicyano-4-aryl-pyridine und ihre Verwendung |
-
2003
- 2003-10-07 EP EP03759728A patent/EP1554267A1/en not_active Withdrawn
- 2003-10-07 CA CA002501534A patent/CA2501534A1/en not_active Abandoned
- 2003-10-07 BR BR0315103-4A patent/BR0315103A/pt not_active IP Right Cessation
- 2003-10-07 CN CNA2003801052200A patent/CN1720243A/zh active Pending
- 2003-10-07 AU AU2003275450A patent/AU2003275450A1/en not_active Abandoned
- 2003-10-07 WO PCT/US2003/031592 patent/WO2004033444A1/en not_active Ceased
- 2003-10-07 RU RU2005110062/04A patent/RU2005110062A/ru not_active Application Discontinuation
- 2003-10-07 PL PL03376405A patent/PL376405A1/xx not_active Application Discontinuation
- 2003-10-07 MX MXPA05003640A patent/MXPA05003640A/es unknown
- 2003-10-07 US US10/679,303 patent/US7098211B2/en not_active Expired - Fee Related
- 2003-10-07 JP JP2004543386A patent/JP2006504738A/ja active Pending
- 2003-10-07 KR KR1020057005919A patent/KR20050070036A/ko not_active Withdrawn
-
2005
- 2005-04-04 ZA ZA200502711A patent/ZA200502711B/en unknown
- 2005-05-03 NO NO20052169A patent/NO20052169L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| AU2003275450A1 (en) | 2004-05-04 |
| PL376405A1 (en) | 2005-12-27 |
| CN1720243A (zh) | 2006-01-11 |
| ZA200502711B (en) | 2006-07-26 |
| JP2006504738A (ja) | 2006-02-09 |
| EP1554267A1 (en) | 2005-07-20 |
| WO2004033444A1 (en) | 2004-04-22 |
| US20040242648A1 (en) | 2004-12-02 |
| RU2005110062A (ru) | 2006-01-10 |
| NO20052169L (no) | 2005-06-08 |
| MXPA05003640A (es) | 2005-11-17 |
| US7098211B2 (en) | 2006-08-29 |
| CA2501534A1 (en) | 2004-04-22 |
| KR20050070036A (ko) | 2005-07-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MXPA05003640A (es) | Compuestos de dihidropiridina que tienen capacidad simultanea para bloquear los canales de calcio del tipo l y para inhibir la actividad de la fosfodiesterasa del tipo 3. | |
| CY1112932T1 (el) | Αναστολεις sμαd7 για τη θεραπευτικη αγωγη ασθενειων του κνς | |
| WO2001021163A3 (en) | Methods and compositions for treating platelet-related disorders using mpl pathway inhibitory agents | |
| MY137348A (en) | Highly selective norepinephrine reuptake inhibitors and methods of using the same | |
| AP2004003069A0 (en) | 3-beta-d-ribofuranosynthiazolo [4-5-d] pyridimine nucleosides and uses thereof. | |
| BRPI0108664B8 (pt) | composto, composição farmacêutica e uso de um composto | |
| EP1712239A3 (en) | Interleukin-1 inhibitors in the treatment of diseases | |
| IS7925A (is) | Hýdroxýetýlamínafleiður til að meðhöndla Alzheimers-sjúkdóm | |
| WO2002045749A8 (en) | Methods for stimulating nervous system regeneration and repair by inhibition phosphodiesterase type 4 | |
| EP1911494A3 (fr) | Utilisation d'oligosaccharides pour stimuler la production de beta-endorphine | |
| WO2003092617A3 (en) | Combinations for the treatment of inflammatory skin disorders | |
| BRPI0408863A (pt) | composto, composição farmacêutica, método para tratar doenças, e, uso de um composto. | |
| CA2337797A1 (en) | Naaladase inhibitors useful as pharmaceutical compounds and compositions | |
| GB0328900D0 (en) | Novel compounds | |
| BR0207272A (pt) | Método de tratamento de doenças ou condições de desmielinação | |
| DK1463735T3 (da) | Imidazo-2,1-B -1,3,4-thiadiazol-sulfonamider | |
| TNSN06403A1 (en) | 3-B-D-RIBOFURANOSYLTHIAZOLO[4,5-d]PYRIDIMINE NUCLEOSIDES AND USES THEREOF | |
| DE602004015089D1 (de) | Pyrroloimidazolderivate ,verfahern zu ihrer herstellung, diese enthaltende zusammensetzungen, und ihre verwendung als nootropika | |
| WO2005035505A3 (en) | Compounds with phosphodiesterase inhibiting and calcium channel blocking activities | |
| EP1870087A3 (fr) | Utilisation de la coumarine, de butylated hydroxyanisole et d'ethoxyquine pour le traitement de la canitie | |
| BR0312778A (pt) | Composição farmacêutica para prevenção ou tratamento de arteriosclerose ou doenças derivadas de arteriosclerose, e, usos de um antagonista de receptor de adp e de um inibidor de acat | |
| MXPA03006372A (es) | Compuestos aromaticos simetricamente disustituidos y composiciones farmaceuticas para inhibir poli (adp-ribosa) glicohidrolasa y metodos para su uso. | |
| AU5857899A (en) | Use of tgf-beta inhibitors for treating cerebral disorders | |
| EP1632235A3 (en) | Use of highly selective norepinephrine reuptake inhibitors for the treatment of mental disorders | |
| HRP20040165B1 (hr) | Upotreba citaloprama u liječenju povišenog krvnogtlaka |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 5A , 6A , E 7A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2073 DE 28/09/2010. |